中国药物警戒 ›› 2021, Vol. 18 ›› Issue (4): 396-399.
DOI: 10.19803/j.1672-8629.2021.04.22

• 综述 • 上一篇    下一篇

麻黄的活性成分与临床应用进展

任海波1, 王迎春1,2,3, 麻景梅1,2,3, 李军山2,3,4, 牛丽颖1,2,3,*   

  1. 1河北中医学院,河北 石家庄050091;
    2河北省中药配方颗粒技术创新中心,河北 石家庄050091;
    3河北省中药材品质评价与标准化工程研究中心,河北 石家庄050091;
    4神威药业集团有限公司,河北 石家庄 051430
  • 收稿日期:2020-06-22 出版日期:2021-04-15 发布日期:2021-04-23
  • 通讯作者: *牛丽颖,女,硕士,教授·博导,中药分析与质量控制研究。E-mail: niuliyingyy@163.com
  • 作者简介:任海波,男,硕士,中药分析及药效物质基础研究。
  • 基金资助:
    河北省自然科学基金资助项目(H2019423050); 河北省中医药管理局科研计划项目(2016009)

Active Ingredients of Ephedra and Their Clinical Application and Contraindications

REN Haibo1, WANG Yingchun1,2,3, MA Jingei1,2,3, LI Junshan2,3,4, NIU Liying1,2,3,*   

  1. 1Hebei University of Chinese Medicine, Shijiazhuang, Hebei 050091, China;
    2Hebei TCM Formula Granule Technology Innovation Center, Shijiazhuang, Hebei 050091, China;
    3Hebei TCM Quality Evaluation and Standardization Engineering Research Center, Shijiazhuang, Hebei 050091, China;
    4Shineway Pharmaceutical Group Company Limited, Shijiazhuang, Hebei 051430, China
  • Received:2020-06-22 Online:2021-04-15 Published:2021-04-23

摘要: 麻黄始载于《神农本草经》,化学成分复杂,具有发汗平喘、利尿、降血脂、抗氧化等多种药理活性,临床应用广泛。本文对麻黄的活性成分、药理作用、临床应用及应用禁忌等方面进行了综述,以期为麻黄及其相关制剂的进一步深入研究和临床用药安全提供参考。

关键词: 麻黄, 活性成分, 不良反应, 应用, 禁忌

Abstract: Ephedra was first documented in "Shen Nong's Materia Medica". It has complex chemical components and has many pharmacological activities such as diaphoresis, relieving asthma, diuresis, lowering blood lipids and anti-oxidation. It has a wide range of clinical applications. This article reviews the active ingredients, pharmacological effects, clinical application and contraindications of Ephedra with a view to providing reference for further in-depth research and safety of clinical medication of Ephedra and its related preparations.

Key words: Ephedra, active ingredient, adverse reaction, application, contraindication

中图分类号: